Topics

FDA Approves Octapharma’s Wilate for the Treatment of Adults and Adolescents with Hemophilia A

14:05 EDT 9 Oct 2019 | Speciality Pharma Journal

HOBOKEN, N.J.–(BUSINESS WIRE)–Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved WILATE® for treatment of adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on demand treatment and control of bleeding episodes. WILATE® is a human plasma-derived, sterile, purified, double virus inactivated von Willebrand Factor (VWF)/coagulation Factor VIII (FVIII) …

Original Article: FDA Approves Octapharma’s Wilate for the Treatment of Adults and Adolescents with Hemophilia A

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Octapharma’s Wilate for the Treatment of Adults and Adolescents with Hemophilia A"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...